We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
GSK said that its Shingrix (Recombinant Zoster Vaccine or RZV) has provided high protection against shingles for over a decade in the ZOSTER-049 Phase 3 trial. The long-term
SCG Cell Therapy and the Agency for Science, Technology and Research (A*STAR) have launched joint laboratories with a funding of nearing S$30m ($22m) to manufacture cellular immunotherapies. Backed
Medincell has entered into a co-development and licensing agreement worth up to nearly $2bn with AbbVie to develop next-generation long-acting injectable (LAI) therapies. The France-based commercial-stage biopharmaceutical licensing
Sentynl Therapeutics has secured authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) of Nulibry (fosdenopterin) for Injection to treat molybdenum cofactor deficiency (MoCD) Type A.
AstraZeneca said that Imfinzi (durvalumab) in combination with standard-of-care chemotherapy doubled the overall survival (OS) rate at three years for patients with advanced biliary tract cancer (BTC) in
GSK today announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for its 5-in-1 meningococcal ABCWY (MenABCWY) vaccine candidate.
ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction
Novartis said that Fabhalta (iptacopan) has shown meaningful and statistically significant proteinuria reduction of 38.3% versus placebo as per pre-specified interim analysis of the Phase 3 APPLAUSE-IgAN study
Germany-based Merck KGaA and Caris Discovery, the therapeutic research division of Caris Life Sciences, have signed a cancer-based antibody-drug conjugates (ADC) development deal worth up to $1.4bn. Under
Basilea Pharmaceutica has received approval from the US Food and Drug Administration (FDA) for Zevtera (ceftobiprole medocaril sodium for injection) for three different indications. The SIX Swiss Exchange-listed